Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs TECH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TECH Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

TECH Overall Winner 6-Pillar Tally: SYRE 0 – 5 TECH (1 Tie) Matrix Metrics: SYRE 0 – 10 TECH

As of Nov 16, 2026, Bio-Techne Corp. (TECH) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas TECH carries 52.4/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs TECH
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 56.6 · SMA20: $98.90 · SMA50: $91.75
TECH NASDAQ Head-to-Head Winner
Bio-Techne Corp.
Biological Products, (No Disgnostic Substances)
$72.79
-0.01% 1D
Market Cap $11.4B
TTM Revenue $1.23B
Forward P/E 42.8x
Beta / 30D Vol 0.37β · 1% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 61
RSI-14: 60.7 · SMA20: $72.71 · SMA50: $72.54

6-Pillar Scorecard Institutional Category Breakdown (SYRE 0 – 5 TECH)

Columns: Metric · SYRE · TECH
1. Valuation Multiples TECH
Forward P/E N/M 42.8x
Trailing P/E N/M 66.8x
PEG Ratio N/M 2.18x
EV / Revenue N/M 9.3x
2. Growth & Scale TECH
Revenue Growth (YoY) +0.0% +4.6%
Earnings Growth (YoY) -99.7% -25.0%
TTM Revenue (USD) N/A $1.23B
Market Cap $9.8B $11.4B
3. Profitability & Quality TECH
Gross Margin N/A 66.2%
Operating Margin 0.0% 21.7%
Net Profit Margin 0.0% 14.0%
Return on Equity (ROE) -35.0% 8.3%
4. Balance Sheet & Cash Flow TECH
Cash Generation (TTM) N/A $325M EBITDA
Cash Flow Margin N/A 26.5% EBITDA Mgn
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $13.79 Book/Sh · 8.3% ROE
Dividend Yield None (0.00%) 0.33%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 87.9% (10th %ile) 40.9% (6th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat TECH
OpEx & R&D Intensity N/A 44.5% of Rev ($547M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (0) vs TECH (10)
Institutional Metric SYRE TECH Criterion Row Edge
Market Capitalization
Scale
$9.8B $11.4B Larger Scale TECH
Trailing P/E Ratio
Valuation
N/M 66.8x Lower Multiple TECH
Forward P/E Ratio
Valuation
N/M 42.8x Lower Multiple TECH
Revenue Growth (YoY)
Growth
+0.0% +4.6% Higher Growth TECH
Operating Margin (TTM)
Profitability
0.0% 21.7% Higher Margin TECH
Net Profit Margin
Profitability
0.0% 14.0% Higher Margin TECH
Return on Equity (ROE)
Capital Efficiency
-35.0% 8.3% Higher ROE TECH
52-Week Range Position
Momentum
88% ($22–$111) 100% ($43–$73) Stronger Trend TECH
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 0.37β · 1% Vol Lower Realized Risk TECH
Unified Institutional Score
Composite Signal
36.1 / 100 (SELL) 52.4 / 100 (HOLD) Higher Composite TECH
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.23B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 66.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.18x PEG · 9.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) $325M EBITDA ($13.79 Book/Sh · 8.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +24.81 pp
SYRE: +25.11% · TECH: +0.3%
3M Horizon TECH +8.08 pp
SYRE: -7.29% · TECH: +0.79%
6M Horizon TECH +21.19 pp
SYRE: +42.64% · TECH: +63.83%
1Y Horizon SYRE +321.92 pp
SYRE: +341.74% · TECH: +19.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs TECH. Trailing 12-month operating profitability (SYRE 0.0% vs TECH 21.7%) and valuation multiples (SYRE N/M vs TECH 42.8x Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
TECH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.23B
Gross Margin66.2%
Op. Margin21.7%
ROE / Fwd P/E8.3% · 42.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TECH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 40.9%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TECH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TECH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.4B market capitalization and 21.7% operating margin.
OpEx & R&D Reinvestment 44.5% of Rev ($547M)
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs TECH Key Questions & Quantitative Answers

As of Nov 16, 2026, Bio-Techne Corp. (TECH) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas TECH carries 52.4/100 (HOLD) at $72.79 (42.8x Forward P/E, 21.7% operating margin). Technically, SYRE sits in a Neutral phase (RSI 56.6, UNCLASSIFIED options structure) and TECH sits in a Neutral phase (RSI 60.7, UNCLASSIFIED options structure).

TECH leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TECH at +4.6% YoY revenue growth and -25.0% YoY earnings growth on $1.23B TTM revenue (66.2% gross margin, 21.7% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $1.23B for TECH. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus 44.5% of Rev ($547M) (0 disclosures) for TECH.

TECH screens cheaper on headline valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas TECH trades at 42.8x Forward P/E, 66.8x Trailing P/E, 2.18x PEG, and 9.3x EV/Revenue (26.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus TECH (8.3% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, TECH carries 40.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 1% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.